NCT01533519View on ClinicalTrials.gov

A Dose Escalation Study of Intranasal Neuropeptide Y in Post Traumatic Stress Disorder (PTSD)

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions
Posttraumatic Stress Disorder
Interventions
DRUG

Neuropeptide Y

Intranasal administration will be administered with a nasal drug delivery device.

Trial Locations (1)

10029

Icahn School of Medicine at Mount Sinai, New York

All Listed Sponsors
lead

James Murrough

OTHER

NCT01533519 - A Dose Escalation Study of Intranasal Neuropeptide Y in Post Traumatic Stress Disorder (PTSD) | Biotech Hunter | Biotech Hunter